French investigators evaluated the efficacy of palbociclib, a CDK4/6 inhibitor, in 71 patients with advanced imatinib- and sunitinib-refractory GIST, 29 had confirmed CDKN2A gene loss. Here, CDKN2A is linked to gastrointestinal stromal tumor.